Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of global pharma major Lupin Limited (Lupin), today announced the commissioning of its dedicated Oncology Block at its Vizag facility in India. The new high-containment unit significantly enhances LMS’s end-to-end Contract Development and Manufacturing capabilities for High Potent Active Pharmaceutical Ingredients. It will support clients across the oncology development lifecycle from preclinical research to commercial manufacturing, addressing growing global demand for oncology drug development and manufacturing.
Spanning 4,270 square meters, the new facility, is equipped with 20 reactors, ranging from 250L to 2000L, with over 20 isolators and advanced containment systems, ensuring exposure levels of ≤0.05 µg/m³. Designed with flexible scale-up capabilities (1–35 kg batch range) and comprehensive environmental controls (≤25°C, ≤45% RH), the facility allows for safe, efficient, and compliant production of oncology APIs that meet global quality standards.
Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, commented, “The inauguration of our Oncology Block in Vizag exemplifies our commitment to advancing oncology research and manufacturing. This state-of-the-art facility enhances our capacity to produce high-quality APIs and develop impactful therapies that benefit patients globally. This marks a major milestone in LMS’s evolution into a dedicated and trusted CDMO partner for oncology innovators. With a focus on containment excellence, scalable solutions tailored to each phase, and scientific rigor, this investment enables our global clients to deliver life-changing oncology treatments to patients more quickly, while upholding the highest safety and compliance standards.”
The new facility integrates the Process Development Laboratory with a dedicated Quality Control laboratory, enabling early-stage route scouting, analytical development, process optimization, and validation—all in one location. Supported by scientists with specialized HPAPI expertise, it guarantees seamless transition from lab-scale synthesis to full-scale commercial manufacturing. The facility features advanced containment infrastructure, with isolator-based operations at every process step, integrated SCADA systems, and a robust effluent detoxification system that complies with global regulatory standards, while also adhering to Lupin’s stringent quality and environmental safety protocols.
With this expansion, LMS strengthens its role as a trusted global CDMO partner for oncology innovators. By integrating Lupin’s scientific legacy with advanced containment facilities and regulatory excellence, LMS provides a cohesive ecosystem that supports quicker, safer, and more efficient development of oncology treatments from concept to commercialization, helping clients worldwide to deliver hope to patients.
Also Read